US4699900A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Xylane sulfates, process for their preparation, and anti-thrombosis and hypolipemic activity thereof
Assignee: Sanofi SA
•
Filing: 1984-03-23
•
Granted: 1987-10-13
•
Expires: 2004-03-23
Abstract
Abstract This invention relates to new xylane sulfates having an apparent molar weight comprised between 7000 and 12000. This invention relates also to a process for their preparation by fractionation, and to the therapeutic application thereof as anti-thrombosis and hypolipemic agents.
Inventors
- 👤 Alain Bayol
- 👤 Jacqueline Lansen
- 👤 Jean P. Maffrand
- 👤 Jean-Marie Pereillo
- 👤 Eric Vallee
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 21:40
CPC Classifications
C; C08; C08B; C08B37/00; C08B37/14; C08B37/0006; C08B37/0057; A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61P; A61P3/00; A61P3/06; A61P7/00; A61P7/02
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
21 words
Xylane sulfates having a sulfatation degree between 1.5 and 2.0 and an apparent molecular weight from about 7,000 to about 12,000.
Claim 2
Dependent Claim
21 words
Xylane sulfates having a sulfatation degree between 1.5 and 2.0 and an apparent molecular weight from about 7,000 to about 12,000.
Claim 3
Dependent Claim
15 words
The xylane sulfates of claim 1 having uronic acid content between 0 and 10 percent.
Claim 4
Dependent Claim
15 words
The xylane sulfates of claim 1 having a pentose content between 30 and 40 percent.
Claim 5
Dependent Claim
38 words
Xylane sulfates having a sulfatation degree between 1.5 and 2.0, an apparent molecular weight from about 7,000 to about 12,000 a uronic acid content between 0 and 10 percent and a pentose content between 30 and 40 percent.
Claim 6
Dependent Claim
38 words
Xylane sulfates having a sulfatation degree between 1.5 and 2.0, an apparent molecular weight from about 7,000 to about 12,000 a uronic acid content between 0 and 10 percent and a pentose content between 30 and 40 percent.
Claim 7
Dependent Claim
28 words
A pharmaceutical composition effective as an anti-thrombotic, anticoagulant, and hypolipemic which comprises a pharmaceutically acceptable carrier and in a therapeutically effective amount, the xylane sulfates of claim 1.
Claim 8
Dependent Claim
16 words
The pharmaceutical composition of claim 5 which is suitable for oral, parenteral, rectal or topical administration.
Claim 9
Dependent Claim
30 words
The pharmaceutical composition of claim 5 which is in unit dosage from wherein each unit dose contains from 0.010 g to 0.250 g of the xylane sulfates of claim 1.
Claim 10
Dependent Claim
22 words
A method for the treatment of venous thrombosis in a host which comprises administering to said host the composition of claim 5.
Claim 11
Dependent Claim
22 words
A method for the treatment of arterial thrombosis in a host which comprises administering to said host the composition of claim 5.
Claim 12
Dependent Claim
21 words
A method for effecting an anticoagulant response in a host which comprises administering to said host the composition of claim 5.
Claim 13
Dependent Claim
22 words
A method for the treatment of atherogenous dyslipemia in a host which comprises administering to said host the composition of claim 5.
Claim 14
Dependent Claim
21 words
A method for the treatment of inflammation in a host which comprises administering to said host the composition of claim 5.
Claim 15
Dependent Claim
25 words
A method for the treatment of rheumatoid arthritis, arthrosis or osteoarthritis in a host which comprises administering to said host the composition of claim 5.
Claim 16
Dependent Claim
45 words
The method for the treatment of a condition selected from the following: venous thrombosis, dyslipemia, inflammation, arthritis and for causing anticoagulation in a host in need thereof which comprises administering the compound of claim 1 to said host and causing an alleviation of said condition.
Claim 17
Dependent Claim
25 words
A pharmaceutical composition effective as an antithrombotic which comprises a pharmaceutically acceptable carrier and in a therapeutically effective amount, the xylane sulfates of claim 1.
Claim 18
Dependent Claim
16 words
The pharmaceutical composition of claim 15 which is suitable for oral, parenteral, rectal or topical adminstration.
Claim 19
Dependent Claim
30 words
The pharmaceutical composition of claim 15 which is in unit dosage form wherein each unit dose contains from 0.010 g to 0.250 g of the xylane sulfates of claim 1.
Claim 20
Dependent Claim
32 words
The method for the treatment of venous thrombosis in a host in need thereof which comprises administering the compound of claim 1 to said host and causing an alleviation of venous thrombosis.
References Cited (Backward Citations)
US3290263A
Cited
US3578657A
Cited
US4098995A
Cited
US4301153A
Cited
US4122250A
Cited
US4221907A
Cited
DE2945595A1
Cited
US4281108A
Cited
FR2543145A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-10-12 | 1991-04-13 | 1991-10-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-10-12 | 1995-04-13 | 1995-10-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-10-12 | 1999-04-13 | 1999-10-13 | $7700.00 | Window Closed / Lapsed |